Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.
TCR sequencing
immunotherapy
pathology
renal cell carcinoma
single-cell RNA-sequencing
tissue-resident
tumor-associated macrophages
tyrosine kinase inhibitors
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
10 05 2021
10 05 2021
Historique:
received:
30
06
2020
revised:
18
01
2021
accepted:
22
03
2021
pubmed:
17
4
2021
medline:
18
11
2021
entrez:
16
4
2021
Statut:
ppublish
Résumé
Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here we perform paired single-cell RNA (scRNA) and T cell receptor (TCR) sequencing of 167,283 cells from multiple tumor regions, lymph node, normal kidney, and peripheral blood of two immune checkpoint blockade (ICB)-naïve and four ICB-treated patients to map the ccRCC immune landscape. We detect extensive heterogeneity within and between patients, with enrichment of CD8A
Identifiants
pubmed: 33861994
pii: S1535-6108(21)00165-3
doi: 10.1016/j.ccell.2021.03.007
pmc: PMC8268947
mid: NIHMS1697391
pii:
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
662-677.e6Subventions
Organisme : NCI NIH HHS
ID : R01 CA205426
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232097
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA082088
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA209975
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as an advisor for Bristol-Myers Squibb, Illumina, Eisai, and An2H. M.S.K. has licensed the use of TMB for the identification of patients who benefit from immune checkpoint therapy to PGDx. S.W. holds equity in Illumina.
Références
Biochim Biophys Acta. 2011 May;1813(5):878-88
pubmed: 21296109
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
Sci Immunol. 2017 Apr 14;2(10):
pubmed: 28738020
Elife. 2020 Mar 18;9:
pubmed: 32187010
Front Physiol. 2014 Mar 05;5:75
pubmed: 24634660
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Cell. 2016 Jan 28;164(3):365-77
pubmed: 26806130
Immunol Rev. 2012 Nov;250(1):102-19
pubmed: 23046125
F1000Res. 2017 Feb 1;6:98
pubmed: 28184299
Elife. 2017 Dec 05;6:
pubmed: 29206104
Clin Exp Immunol. 2018 Oct;194(1):39-53
pubmed: 30009527
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
J Immunol. 2011 Apr 1;186(7):4285-94
pubmed: 21383244
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Clin Cancer Res. 2007 Mar 15;13(6):1757-61
pubmed: 17363529
JCI Insight. 2019 Oct 3;4(19):
pubmed: 31465302
Nat Genet. 2017 Mar 30;49(4):482-483
pubmed: 28358132
Nat Biotechnol. 2019 Apr;37(4):451-460
pubmed: 30899105
Front Immunol. 2018 Oct 26;9:2472
pubmed: 30416504
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Front Immunol. 2018 Mar 26;9:515
pubmed: 29632527
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Elife. 2018 Aug 28;7:
pubmed: 30152754
Nat Commun. 2017 May 24;8:15221
pubmed: 28537262
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Immunity. 2010 Jul 23;33(1):7-9
pubmed: 20643334
Oncotarget. 2016 Apr 26;7(17):24527-36
pubmed: 27016418
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
EMBO Mol Med. 2014 Jun 27;6(8):1075-89
pubmed: 24972930
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Nat Biotechnol. 2020 Oct;38(10):1194-1202
pubmed: 32341563
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
Nat Rev Immunol. 2014 Jun;14(6):392-404
pubmed: 24854589
Nature. 2020 Nov;587(7832):115-120
pubmed: 33087928
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Bioinformatics. 2015 Jun 15;31(12):1974-80
pubmed: 25805722
Cancer Discov. 2019 Apr;9(4):510-525
pubmed: 30622105
Genome Med. 2013 Oct 30;5(10):98
pubmed: 24172704
Cancer Discov. 2020 Jan;10(1):40-53
pubmed: 31732494
Trends Immunol. 2019 Aug;40(8):735-747
pubmed: 31255505
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32728699
Nat Med. 2019 Nov;25(11):1715-1720
pubmed: 31700181
Clin Exp Allergy. 2001 Aug;31(8):1173-88
pubmed: 11529886
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
Mol Biol Evol. 2018 Sep 1;35(9):2145-2158
pubmed: 29893875
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Clin Cancer Res. 2013 Jul 1;19(13):3681-92
pubmed: 23685835
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Biotechnol. 2018 Jun;36(5):421-427
pubmed: 29608177
Expert Rev Clin Immunol. 2014 May;10(5):593-619
pubmed: 24678812
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
F1000Res. 2016 Aug 31;5:2122
pubmed: 27909575
Nature. 2019 Mar;567(7749):525-529
pubmed: 30814730
Cell. 2020 Apr 16;181(2):236-249
pubmed: 32302568
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Science. 1974 Sep 6;185(4154):862-4
pubmed: 4843792
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Cancer Res. 2018 Aug 1;78(15):4253-4269
pubmed: 29789416
Nat Cell Biol. 2016 May;18(5):549-60
pubmed: 27088855
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
F1000Res. 2018 Aug 15;7:1297
pubmed: 30228881
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nature. 2018 Dec;564(7735):219-224
pubmed: 30518857
J Immunol. 2006 May 15;176(10):5825-32
pubmed: 16670288
Nat Med. 2019 Oct;25(10):1540-1548
pubmed: 31591602
Front Immunol. 2019 Jul 31;10:1516
pubmed: 31417541
J Exp Med. 2015 Aug 24;212(9):1433-48
pubmed: 26261265
Nature. 2020 Mar;579(7798):274-278
pubmed: 32103181
Nature. 2013 Apr 25;496(7446):445-55
pubmed: 23619691
Nature. 2017 Jul 6;547(7661):89-93
pubmed: 28636592
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Nat Commun. 2013;4:2612
pubmed: 24113773
J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285
pubmed: 31693980
Cancer Metastasis Rev. 2010 Jun;29(2):309-16
pubmed: 20405169
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Eur J Cancer. 2016 Jun;60:1-11
pubmed: 27038842
Nat Commun. 2019 Sep 27;10(1):4401
pubmed: 31562311
Nat Protoc. 2020 Apr;15(4):1484-1506
pubmed: 32103204
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Nat Cancer. 2020 May;1(5):546-561
pubmed: 32803172
Nat Genet. 2016 Jul;48(7):725-32
pubmed: 27240091
J Immunol. 2014 May 15;192(10):4541-50
pubmed: 24740509
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581